Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Glaukos Corporation Common Stock
(NY:
GKOS
)
119.67
+6.03 (+5.31%)
Streaming Delayed Price
Updated: 12:28 PM EDT, Jun 4, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Glaukos Corporation Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Glaukos Announces Participation in Upcoming Investor Conferences
May 12, 2026
From
Glaukos Corporation
Via
Business Wire
Glaukos (GKOS) Q1 2026 Earnings Transcript
↗
April 29, 2026
Glaukos (GKOS) Q1 2026 Earnings Transcript
Via
The Motley Fool
Glaukos Corp (NYSE:GKOS) Shares Surge on Record Sales and Raised Guidance After Q1 Beat
↗
April 29, 2026
Via
Chartmill
Glaukos Announces First Quarter 2026 Financial Results
April 29, 2026
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces the Release of its 2025 Sustainability Report
April 16, 2026
From
Glaukos Corporation
Via
Business Wire
Glaukos Corp (NYSE:GKOS) Shows High-Growth Momentum and Fits Key Trend Template Rules
↗
April 03, 2026
Via
Chartmill
Glaukos Corp (NYSE:GKOS) Reports Record 2025 Sales but Shares Dip on Wider Loss, Conservative Outlook
↗
February 17, 2026
Via
Chartmill
Glaukos Receives Permanent J-code for Epioxa™
April 15, 2026
From
Glaukos Corporation
Via
Business Wire
Glaukos to Release First Quarter 2026 Financial Results after Market Close on April 29
April 08, 2026
From
Glaukos Corporation
Via
Business Wire
Glaukos to Present Multiple Scientific Abstracts at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
April 06, 2026
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Commercial Availability of Epioxa™, a Transformative Innovation in Interventional Keratoconus Care
March 19, 2026
From
Glaukos Corporation
Via
Business Wire
Xenon Stock at $42: What to Know of a $75 Million Trim Ahead of March Phase 3 Data
↗
February 19, 2026
This biotech specializes in clinical-stage therapies for neurological disorders, with a pipeline targeting epilepsy and related conditions.
Via
The Motley Fool
Topics
Regulatory Compliance
Inside a $58 Million Bet on Kodiak Amid $184 Million Offering and Phase 3 Readouts Ahead
↗
February 19, 2026
Focused on retinal disease therapies, Kodiak Sciences leads with clinical-stage candidates targeting major unmet needs in ophthalmology.
Via
The Motley Fool
Topics
Regulatory Compliance
This Fund Just Disclosed a New $55 Million Bet on Centessa Amid 53% Stock Rally and CEO Transition
↗
February 19, 2026
This UK-based biotech advances clinical-stage therapies for rare diseases, targeting specialty care markets with a diversified pipeline.
Via
The Motley Fool
CG Oncology Soars 102% in a Year, but One Investor Just Disclosed a $58.5 Million Sale
↗
February 19, 2026
This clinical-stage biotech develops bladder-sparing therapies for high-risk cancer patients with limited treatment options.
Via
The Motley Fool
Topics
Regulatory Compliance
BrightSpring Stock Up 86% as Braidwell Takes $45 Million Stake in Healthcare Services Provider
↗
February 19, 2026
BrightSpring Health Services delivers integrated pharmacy and clinical care to Medicare, Medicaid, and insured patients nationwide.
Via
The Motley Fool
Topics
Regulatory Compliance
Glaukos (GKOS) Q4 2025 Earnings Call Transcript
↗
February 17, 2026
Glaukos (GKOS) Q4 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Glaukos Announces Fourth Quarter and Full Year 2025 Financial Results
February 17, 2026
From
Glaukos Corporation
Via
Business Wire
Director Sells GKOS 15,000 Shares for $1.9 Million
↗
January 31, 2026
This ophthalmic device maker, focused on glaucoma solutions, reported a notable insider sale after a challenging year for its stock.
Via
The Motley Fool
Topics
Regulatory Compliance
Glaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose® TR
January 28, 2026
From
Glaukos Corporation
Via
Business Wire
Glaukos to Release Fourth Quarter and Full Year 2025 Financial Results after Market Close on February 17
January 20, 2026
From
Glaukos Corporation
Via
Business Wire
These stocks are moving in today's after hours session
↗
January 13, 2026
Via
Chartmill
Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Sales and Reaffirms 2026 Revenue Guidance
January 13, 2026
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Participation in J.P. Morgan Healthcare Conference
December 16, 2025
From
Glaukos Corporation
Via
Business Wire
Brown Capital Sells $35 Million in Glaukos Stock After Sharp Sell-Off
↗
November 06, 2025
Brown Capital Sells $35 Million in Glaukos Stock After Sharp Sell-Off
Via
The Motley Fool
Topics
Regulatory Compliance
Glaukos Announces Participation in Upcoming Investor Conferences
November 03, 2025
From
Glaukos Corporation
Via
Business Wire
Why Glaukos Stock Zoomed Almost 14% Higher on Thursday
↗
October 30, 2025
The company's recent past featured robust growth, and it anticipates continued rises into the near future.
Via
The Motley Fool
Glaukos (GKOS) Q3 2025 Earnings Call Transcript
↗
October 30, 2025
Glaukos (GKOS) Q3 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Cardinal Health Posts Upbeat Q1 Results, Joins Guardant Health, Glaukos, C.H. Robinson And Other Big Stocks Moving Higher On Thursday
↗
October 30, 2025
Via
Benzinga
Get insights into the top gainers and losers of Thursday's pre-market session.
↗
October 30, 2025
The US market is yet to commence its session on Thursday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Via
Chartmill
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
